Vaccination with recombinant N-terminal domain of Als1p improves survival during murine disseminated candidiasis by enhancing cell-mediated, not humoral, immunity

Infection and Immunity

Volumn 73, Issue 2, 2005, Pages 999-1005

  Ibrahim, Ashraf S ^a,b   Spellberg, Brad J ^a,b   Avenissian, Valentina ^a   Fu, Yue ^a,b   Filler, Scott G ^a,b   Edwards Jr , John E ^a,b  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALS1P PROTEIN; CELL SURFACE PROTEIN; CYTOKINE; FUNGAL PROTEIN; RALS1P N VACCINE; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDIASIS; CELL ADHESION; CELLULAR IMMUNITY; CELLULAR IMMUNODEFICIENCY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DELAYED HYPERSENSITIVITY; DISEASE DURATION; DRUG MECHANISM; HOSPITAL INFECTION; HUMORAL IMMUNE DEFICIENCY; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOMODULATION; IN VIVO STUDY; MORTALITY; MOUSE; MOUSE STRAIN; N TERMINAL DOMAIN; NONHUMAN; NUDE MOUSE; OPPORTUNISTIC INFECTION; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN DOMAIN; RISK FACTOR; SEPSIS; SPLEEN CELL; TH1 CELL; VACCINATION;

ANIMALS; ANTIBODIES; ANTIBODY FORMATION; CANDIDA ALBICANS; CANDIDIASIS; FUNGAL PROTEINS; HYPERSENSITIVITY, DELAYED; IMMUNITY, CELLULAR; MICE; PEPTIDE FRAGMENTS; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; TH1 CELLS; TIME FACTORS; VACCINATION;

EID: 12844260839     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.73.2.999-1005.2005     Document Type: Article

References (67)

1. Arrowood, J. R., and M. S. Hayney. 2002. Immunization recommendations for adults with cancer. Ann. Pharmacother. 36:1219-1229.
2. Bromuro, C., A. Torosantucci, P. Chiani, S. Conti, L. Polonelli, and A. Cassone. 2002. Interplay between protective and inhibitory antibodies dictates the outcome of experimentally disseminated candidiasis in recipients of a Candida albicans vaccine. Infect. Immun. 70:5462-5470.
3. Bystricky, S., E. Paulovicova, and E. Machova. 2003. Candida albicans mannan-protein conjugate as vaccine candidate. Immunol. Lett. 85:251-255.
4. Cardenas-Freytag, L., E. Cheng, P. Mayeux, J. E. Domer, and J. D. Clements. 1999. Effectiveness of a vaccine composed of heat-killed Candida albicans and a novel mucosal adjuvant, LT(R192G), against systemic candidiasis. Infect. Immun. 67:826-833.
5. Casadevall, A., and L. A. Pirofski. 2003. Antibody-mediated regulation of cellular immunity and the inflammatory response. Trends Immunol. 24:474-478.
6. Cenci, E., A. Mencacci, G. Del Sero, F. Bistoni, and L. Romani. 1997. Induction of protective Th1 responses to Candida albicans by antifungal therapy alone or in combination with an interleukin-4 antagonist. J. Infect. Dis. 176:217-226.
7. + lymphocytes in protective immunity to systemic Candida albicans infection in mice. Infect. Immun. 57:3581-3587.
8. Chokephaibulkit, K., W. Phongsamart, N. Vanprapar, T. Chotpitayasunondh, and S. Chearskul. 2004. Catch-up vaccination against Haemophilus influenzae type b in human immunodeficiency virus-infected Thai children older than 2 years old. Vaccine 22:2018-2022.
9. Collin, B., C. J. Clancy, and M. H. Nguyen. 1999. Antifungal resistance in non-albicans Candida species. Drug Resist. Updates 2:9-14.
10. De Sousa dos Santos, S., M. H. Lopes, V. Simonsen, and H. H. Caiaffa Filho. 2004. Haemophilus influenzae type b immunization in adults infected with the human immunodeficiency virus. AIDS Res. Hum. Retrovir. 20:493-496.
11. Dockrell, D. H., G. A. Poland, J. M. Steckelberg, P. C. Wollan, S. R. Strickland, and C. Pomeroy. 1999. Immunogenicity of three Haemophilus influenzae type b protein conjugate vaccines in HIV seropositive adults and analysis of predictors of vaccine response. Vaccine 17:2779-2785.
12. Feldman, S., F. Gigliotti, J. L. Shenep, P. K. Roberson, and L. Lett. 1990. Risk of Haemophilus influenzae type b disease in children with cancer and response of immunocompromised leukemic children to a conjugate vaccine. J. Infect. Dis. 161:926-931.
13. Fu, Y., A. S. Ibrahim, D. C. Sheppard, Y.-C. Chen, S. W. French, J. E. Cutler, S. G. Filler, and J. E. J. Edwards. 2002. Candida albicans Als1p: an adhesin that is a downstream effector of the EFG1 filamentation pathway. Mol. Microbiol. 44:61-72.
14. Fu, Y., G. Rieg, W. A. Fonzi, P. H. Belanger, J. E. Edwards, Jr., and S. G. Filler. 1998. Expression of the Candida albicans gene ALS1 in Saccharomyces cerevisiae induces adherence to endothelial and epithelial cells. Infect. Immun. 66:1783-1786.
15. Gaur, N. K., and S. A. Klotz. 1997. Expression, cloning, and characterization of a Candida albicans gene, ALA1, that confers adherence properties upon Saccharomyces cerevisiae for extracellular matrix proteins. Infect. Immun. 65:5289-5294.
16. Gudlaugsson, O., S. Gillespie, K. Lee, J. Vande Berg, J. Hu, S. Messer, L. Herwaldt, M. Pfaller, and D. Diekema. 2003. Attributable mortality of nosocomial candidemia, revisited. Clin. Infect. Dis. 37:1172-1177.
17. Guerrero, M., S. Kruger, A. Saitoh, F. Sorvillo, K. J. Cheng, C. French, and G. Beall. 1999. Pneumonia in HIV-infected patients: a case-control survey of factors involved in risk and prevention. AIDS 13:1971-1975.
18. Han, Y., and J. E. Cutler. 1995. Antibody response that protects against disseminated candidiasis. Infect. Immun. 63:2714-2719.
19. Han, Y., T. Kanbe, R. Cherniak, and J. E. Cutler. 1997. Biochemical characterization of Candida albicans epitopes that can elicit protective and non-protective antibodies. Infect. Immun. 65:4100-4107.
20. Han, Y., M. H. Riesselman, and J. E. Cutler. 2000. Protection against candidiasis by an immunoglobulin G3 (IgG3) monoclonal antibody specific for the same mannotriose as an IgM protective antibody. Infect. Immun. 68:1649-1654.
21. Han, Y., M. A. Ulrich, and J. E. Cutler. 1999. Candida albicans mannan extract-protein conjugates induce a protective immune response against experimental candidiasis. J. Infect. Dis. 179:1477-1484.
22. Ibrahim, A. S., S. G. Filler, M. S. Alcouloumre, T. R. Kozel, J. E. Edwards, Jr., and M. A. Ghannoum. 1995. Adherence to and damage of endothelial cells by Cryptococcus neoformans in vitro: role of the capsule. Infect. Immun. 63:4368-4374.
23. Kelly, S. L., D. C. Lamb, D. E. Kelly, N. J. Manning, J. Loeffler, B. Bebart, U. Schumacher, and B. Einsele. 1997. Resistance to fluconazole and cross-resistance to amphotericin B in Candida albicans from AIDS patients caused by defective sterol 65,6-desaturation. FEBS Lett. 400:80-82.
24. Kemper, C. A., R. Haubrich, I. Frank, G. Dubin, C. Buscarino, J. A. McCutchan, and S. C. Deresinski. 2003. Safety and immunogenicity of hepatitis A vaccine in human immunodeficiency virus-infected patients: a double-blind, randomized, placebo-controlled trial. J. Infect. Dis. 187:1327-1331.
25. King, J. C., Jr., P. E. Vink, J. J. Farley, M. Parks, M. Smilie, D. Madore, R. Lichenstein, and F. Malinoski. 1996. Comparison of the safety and immunogenicity of a pneumococcal conjugate with a licensed polysaccharide vaccine in human immunodeficiency virus and non-human immunodeficiency virus-infected children. Pediatr. Infect. Dis. J. 15:192-196.
26. Klugman, K. P., S. A. Madhi, R. E. Huebner, R. Kohberger, N. N. Mbelle, and N. Pierce. 2003. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N. Engl. J. Med. 349:1341-1348.
27. Kroon, F. P., J. T. van Dissel, E. Ravensbergen, P. B. Nibbering, and R. van Furth. 1999. Impaired antibody response after immunization of HIV-infected individuals with the polysaccharide vaccine against Salmonella typhi (Typhim-Vi). Vaccine 17:2941-2945.
28. Kuruganti, U., L. A. Henderson, R. E. Garner, R. Asofsky, P. J. Baker, and J. E. Domer. 1988. Nonspecific and Candida-specific immune responses in mice suppressed by chronic administration of anti-mu. J. Leukoc. Biol. 44:422-433.
29. Leung, T. F., C. K. Li, E. C. Hung, P. K. Chan, C. W. Mo, R. P. Wong, and K. W. Chik. 2004. Immunogenicity of a two-dose regime of varicella vaccine in children with cancers. Eur. J. Haematol. 72:353-357.
30. Levin, M. J., A. A. Gershon, A. Weinberg, S. Blanchard, B. Nowak, P. Palumbo, and C. Y. Chan. 2001. Immunization of HIV-infected children with varicella vaccine. J. Pediatr. 139:305-310.
31. Li, R. K., and J. E. Cutler. 1993. Chemical definition of an epitope/adhesin molecule on Candida albicans. J. Biol. Chem. 268:18293-18299.
32. Loza, L., Y. Fu, A. S. Ibrahim, D. C. Sheppard, S. G. Filler, and J. E. Edwards, Jr. 2004. Functional analysis of the Candida albicans ALS1 gene product. Yeast 21:473-482.
33. Madhi, S. A., K. Petersen, M. Khoosal, R. E. Huebner, N. Mbelle, R. Mothupi, H. Saloojee, H. Crewe-Brown, and K. P. Klugman. 2002. Reduced effectiveness of Haemophilus influenzae type b conjugate vaccine in children with a high prevalence of human immunodeficiency virus type 1 infection. Pediatr. Infect. Dis. J. 21:315-321.
34. Martino, P., C. Girmenia, A. Micozzi, R. Raccah, G. Gentile, M. Venditti, and F. Mandelli. 1993. Fungemia in patients with leukemia. Am. J. Med. Sci. 306:225-232.
35. Matthews, R. C., G. Rigg, S. Hodgetts, T. Carter, C. Chapman, C. Gregory, C. Illidge, and J. Burnie. 2003. Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90. Antimicrob. Agents Chemother. 47:2208-2216.
36. + T helper type 1 cell responses to Candida albicans. J. Exp. Med. 187:307-317.
37. + T-helper-cell responses in mice with low-level Candida albicans infection. Infect. Immun. 64:4907-4914.
38. Muller, F. M., M. Weig, J. Peter, and T. J. Walsh. 2000. Azole cross-resistance to ketoconazole, fluconazole, itraconazole and voriconazole in clinical Candida albicans isolates from HIV-infected children with oropharyngeal candidosis. J. Antimicrob. Chemother. 46:338-340.
39. Nordoy, T., I. S. Aaberge, A. Husebekk, H. H. Samdal, S. Steinert, H. Melby, and A. Kolstad. 2002. Cancer patients undergoing chemotherapy show adequate serological response to vaccinations against influenza virus and Streptococcus pneumoniae. Med. Oncol. 19:71-78.
40. Nucci, M., W. Pulcheri, N. Spector, A. P. Bueno, P. C. Bacha, M. J. Caiuby, A. Derossi, R. Costa, J. C. Morais, and H. P. de Oliveira. 1995. Fungal infections in neutropenic patients: an 8-year prospective study. Rev. Inst. Med. Trop. Sao Paulo 37:397-406.
41. Oomura, Y., K. Sasaki, A. Li, H. Yoshii, Y. Fukata, H. Yago, H. Kimura, I. Tooyama, K. Hanai, Y. Nomura, and N. Yanaihara. 1996. Protection against impairment of memory and immunoreactivity in senescence-accelerated mice by acidic fibroblast growth factor. Ann. N. Y. Acad. Sci. 786:337-347.
42. Parish, C. R. 1971. Immune response to chemically modified flagellin. I. Induction of antibody tolerance to flagellin by acetoacetylated derivatives of the protein. J. Exp. Med. 134:1-20.
43. Parish, C. R. 1971. Immune response to chemically modified flagellin. II. Evidence for a fundamental relationship between humoral and cell-mediated immunity. J. Exp. Med. 134:21-47.
44. Parish, C. R., and F. Y. Liew. 1972. Immune response to chemically modified flagellin. III. Enhanced cell-mediated immunity during high and low zone antibody tolerance to flagellin. J. Exp. Med. 135:298-311.
45. Pearsall, N. N., B. L. Adams, and R. Bunni. 1978. Immunologic responses to Candida albicans. III. Effects of passive transfer of lymphoid cells or serum on murine candidiasis. J. Immunol. 120:1176-1180.
46. Read, J. S., C. E. Frasch, K. Rich, G. A. Fitzgerald, J. D. Clemens, J. Pitt, S. I. Pelton, I. C. Hanson, E. Handelsman, C. Diaz, and M. G. Fowler. 1998. The immunogenicity of Haemophilus influenzae type b conjugate vaccines in children born to human immunodeficiency virus-infected women. Pediatr. Infect. Dis. J. 17:391-397.
47. Rhyne, A. L., and R. G. Steel. 1967. A multiple comparisons sign test: all pairs of treatments. Biometrics 23:539-549.
48. + T helper cell 1 development in interleukin 6-deficient mice infected with Candida albicans. J. Exp. Med. 183:1345-1355.
49. Romani, L., A. Mencacci, U. Grohmann, S. Mocci, P. Mosci, P. Puccetti, and F. Bistoni. 1992. Neutralizing antibody to interleukin 4 induces systemic protection and T helper type 1-associated immunity in murine candidiasis. J. Exp. Med. 176:19-25.
50. Romani, L., A. Mencacci, L. Tonnetti, R. Spaccapelo, E. Cenci, P. Puccetti, S. F. Wolf, and F. Bistoni. 1994. IL-12 is both required and prognostic in vivo for T helper type 1 differentiation in murine candidiasis. J. Immunol. 153:5167-5175.
51. Romani, L., P. Puccetti, A. Mencacci, E. Cenci, R. Spaccapelo, L. Tonnetti, U. Grohmann, and F. Bistoni. 1994. Neutralization of IL-10 up-regulates nitric oxide production and protects susceptible mice from challenge with Candida albicans. J. Immunol. 152:3514-3521.
52. Rutstein, R. M., B. J. Rudy, and A. Cnaan. 1996. Response of human immunodeficiency virus-exposed and -infected infants to Haemophilus influenzae type b conjugate vaccine. Arch. Pediatr. Adolesc. Med. 150:838-841.
53. Schaberg, D. R., D. H. Culver, and R. P. Gaynes. 1991. Major trends in the microbial etiology of nosocomial infection. Am. J. Med. 91:72S-75S.
54. Sheppard, D. C., M. R. Yeaman, W. H. Welch, Q. T. Phan, Y. Fu, A. S. Ibrahim, S. G. Filler, M. Zhang, A. J. Waring, and J. E. Edwards, Jr. 2004. Functional and structural diversity in the Als protein family of Candida albicans. J. Biol. Chem. 279:30480-30489.
55. Sinsalo, M., J. Aittoniemi, H. Kayhty, and J. Vilpo. 2002. Haemophilus influenzae type b (Hib) antibody concentrations and vaccination responses in patients with chronic lymphocytic leukaemia: predicting factors for response. Leuk. Lymphoma 43:1967-1969.
56. Somjee, S., S. Pai, P. Parikh, S. Banavali, R. Kelkar, and S. Advani. 2002. Passive active prophylaxis against hepatitis B in children with acute lymphoblastic leukemia. Leuk. Res. 26:989-992.
57. Spellberg, B., and J. E. Edwards, Jr. 2001. Type 1/type 2 immunity in infectious diseases. Clin. Infect. Dis. 32:76-102.
58. Spellberg, B. J., and J. E. Edwards, Jr. 2002. The pathophysiology and treatment of Candida sepsis. Curr. Infect. Dis. Rep. 4:387-399.
59. Spellberg, B. J., D. Johnston, Q. T. Phan, J. E. Edwards, Jr., S. W. French, A. Ibrahim, and S. G. Filler. 2003. Parenchymal organ, and not splenic, immunity correlates with host survival during disseminated candidiasis. Infect. Immun. 71:5756-5764.
60. Tabeta, H., Y. Mikami, F. Abe, Y. Ommura, and T. Arai. 1984. Studies on defense mechanisms against Candida albicans infection in congenitally athymic nude (nu/nu) mice. Mycopathologia 84:107-113.
61. Tasker, S. A., G. A. Schnepf, M. Lim, H. E. Caraviello, A. Armstrong, M. Bavaro, B. K. Agan, J. Delmar, N. Aronson, M. R. Wallace, and J. D. Grabenstein. 2004. Unintended smallpox vaccination of HIV-1-infected individuals in the United States military. Clin. Infect. Dis. 38:1320-1322.
62. Tedaldi, E. M., R. K. Baker, A. C. Moorman, K. C. Wood, J. Fuhrer, R. E. McCabe, and S. D. Holmberg. 2004. Hepatitis A and B vaccination practices for ambulatory patients infected with HIV. Clin. Infect. Dis. 38:1478-1484.
63. Valentin, A., R. Le Guennec, E. Rodriguez, J. Reynes, M. Mallie, and J. M. Bastide. 1996. Comparative resistance of Candida albicans clinical isolates to fluconazole and itraconazole in vitro and in vivo in a murine model. Antimicrob. Agents Chemother. 40:1342-1345.
64. Wagner, R. D., A. Vazquez-Torres, J. Jones-Carson, T. Warner, and E. Balish. 1996. B cell knockout mice are resistant to mucosal and systemic candidiasis of endogenous origin but susceptible to experimental systemic candidiasis. J. Infect. Dis. 174:589-597.
65. Wey, S. B., M. Mori, M. A. Pfaller, R. F. Woolson, and R. P. Wenzel. 1988. Hospital-acquired candidemia: the attributable mortality and excess length of stay. Arch. Intern. Med. 148:2642-2645.
66. Zaragoza, O., and A. Casadevall. 2004. Antibodies produced in response to Cryptococcus neoformans pulmonary infection in mice have characteristics of nonprotective antibodies. Infect. Immun. 72:4271-4274.
67. Zhao, X., C. Pujol, D. R. Soll, and L. L. Hoyer. 2003. Allelic variation in the contiguous loci encoding Candida albicans ALS5, ALS1 and ALS9. Microbiology 149:2947-2960.